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1678Objectives: Lung volume reduction surgery (LVRS) provides palliation and improved quality of life in select
patients with end-stage chronic obstructive pulmonary disease (COPD). The effect of previous LVRS on lung
transplant outcomes has been inadequately studied. We report our experience in the largest single institution
series of these combined procedures.
Methods: The records of 472 patients with COPD undergoing lung transplantation or LVRS between 1995 and
2010 were reviewed. Outcomes of patients undergoing transplant after LVRS were compared with outcomes of
patients undergoing transplant or LVRS alone. Survival was compared using log-rank tests and the Kaplan-
Meier method.
Results: Demographics, comorbidities, and spirometry were similar at the time of transplantation. Patients who
had undergone lung transplant after LVRS had longer transplant operative times (mean 4.4 vs 5.6 hours;
P¼ .020) and greater hospital length of stay (mean 17.6 vs 29.1 days; P¼ .005). Thirty-day mortality and major
morbidity were similar. Posttransplant survival was reduced for transplant after LVRS (median, 49 months; 95%
confidence interval [CI], 16, 85 months) compared with transplant alone (median, 96 months; 95% CI, 82, 106
months; P¼ .008). The composite benefit of combined procedures, defined as bridge from LVRS to transplant of
55 months and posttransplant survival of 49 months (total 104 months), was comparable with survival of patients
undergoing either procedure alone.
Conclusions: Lung transplant after LVRS leads to minimal additional perioperative risk. The reduced posttrans-
plant survival in patients undergoing combined procedures is in contradistinction to reports from other smaller
series. When determining the best surgical treatment for patients with more severe disease, the benefit
of LVRS before transplant should be weighed against the consequence of reduced posttransplant survival.
(J Thorac Cardiovasc Surg 2014;147:1678-83)Supplemental material is available online.
Chronic obstructive pulmonary disease (COPD) is the third
leading cause of death in the United States accounting for
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The Journal of Thoracic and Cardiovascular SurFor many patients, surgical intervention offers the best
long-term outcomes. Surgical treatment of end-stage
COPD consists of either lung volume reduction surgery
(LVRS) or lung transplantation. Early results from LVRS
in the 1990s, demonstrated significant improvements in pul-
monary function tests (PFTs), dyspnea, and quality of
life.2,3 The results were further substantiated by the
publication of the National Emphysema Treatment Trial
(NETT), which refined patient selection and identified
those who derive optimal benefit from this surgical
therapy.4 Lung transplantation has also benefitted patients
with limited life expectancy from end-stage COPD. It is
associated with improved physical and social functioning,
mental health, health perceptions, and patient-reported
quality of life.5-8 However, not all patients with end-stage
COPD meet the requirements for lung transplantation, and
for those who do, the shortage of organ donors limits the
number of lung transplants that can be performed. Thus,
many have advocated for use of LVRS as a palliative surgi-
cal procedure in lieu of or as a bridge to lung transplanta-
tion. The posttransplant outcomes of these surgical
procedures used in combination have been incompletely
described. For this study, we reviewed our institutionalgery c May 2014
Abbreviations and Acronyms
COPD ¼ chronic obstructive pulmonary disease
CI ¼ confidence interval
FEV1 ¼ forced expiratory volume in 1 second
ICU ¼ intensive care unit
LAS ¼ lung allocation score
LVRS ¼ lung volume reduction surgery
NETT ¼ National Emphysema Treatment Trial
PFT ¼ pulmonary function tests
PVR ¼ pulmonary vascular resistance
RV ¼ residual volume
SD ¼ standard deviation
Backhus et al Cardiothoracic Transplantationexperience with patients with end-stage COPD who under-
went LVRS, lung transplant, or both procedures to charac-
terize posttransplant outcomes.T
XMETHODS
Patient Cohort and Variables
The University of Washington Investigational Review Board for human
subjects approved the study protocol. We reviewed the records of 473
adults with end-stage COPD undergoing lung transplantation or LVRS at
our institution between 1995 and 2010. Patients presented to our multidis-
ciplinary clinic for evaluation for either or both surgical procedures. A
nurse coordinator screened patients who were further reviewed by 2 physi-
cians before surgical consultation. The University of Washington was a
participating site for the NETT and thus patients evaluated in the clinic
during this time were also considered for enrollment in this trial. Patients
undergoing LVRS after publication of the NETT results were selected
based on NETT criteria. A total of 138 patients underwent lung transplan-
tation and 335 patients underwent LVRS as their initial surgical therapy. Of
the latter, 37 patients subsequently received a lung transplant. The record of
1 patient undergoing transplant after LVRS had insufficient follow-up data
and was excluded from our analyses.
Clinical variables included patient demographics, PFTs, and preopera-
tive comorbidities. The primary outcome of interest was overall survival
after LVRS or transplantation. Secondary outcomes included perioperative
and long-term complications after either procedure.
LVRS and Lung Transplantation Surgical
Techniques
LVRS was performed via median sternotomy or video-assisted tech-
nique with sequential stapling and buttress. Areas of most severe hyperin-
flation, identified using preoperative imaging and intraoperative
assessment, were selected for resection. Bilateral lung transplant was
performed using a bilateral sequential technique via anterior thoracotomies
with or without transverse sternotomy. Single lung transplant was per-
formed via unilateral anterior thoracotomy. Cardiopulmonary bypass was
used only in select cases.
Statistical Analysis
Descriptive statistics were expressed by median (95% confidence inter-
val [CI]) ormean (standard deviation [SD]). Comparisons of categorical var-
iables were made using the c2 test or the Fisher exact test when applicable.
Continuous variables were compared using the Student t test or analysis of
variance. Survival analysis was conducted using the Kaplan-Meier methodThe Journal of Thoracic and Carand comparedusing the log-rank test.All statistical analyseswere performed
using STATAversion 12.1 (Stata Corporation, College Station, Tex).
RESULTS
Patients undergoing LVRS alone were older (mean 63.3
years, SD 7.6 years) than patients who had lung transplan-
tation after LVRS (mean 54.7 years, SD 6.9 years) or those
undergoing lung transplantation alone (mean 57.8 years, SD
6.0 years) (P ¼ .024). Mean follow-up after LVRS was 19
months (SD 26 months) for LVRS alone. Mean follow-up
after transplant was 50 months (SD 44 months) for com-
bined LVRS and lung transplant, and 59 months (SD 38
months) for transplant alone (Table 1).
Transplantation Outcomes
When we compared posttransplant outcomes for those
patients undergoing transplant after LVRS or transplant
alone, we found similar pretransplant comorbidities and
PFTs. Pretransplant pulmonary vascular resistance (PVR)
was higher in those patients presenting for transplant after
LVRS than patients undergoing transplant alone (2.2 vs
4.0 Woods units; P ¼ .002) (Table 2). Transplant operative
times were also longer for patients with transplant after
LVRS (5.57 hours, SD 1.24 hours vs 4.40 hours, SD 1.20
hours; P ¼ .020). All other intraoperative variables,
including the need for cardiopulmonary bypass, estimated
blood loss, and fluid and blood transfusion requirements,
were similar between groups. Perioperative mortality was
not significantly different between groups (30-daymortality
5.6% for transplant after LVRS vs 3.6% for transplant
alone; P ¼ .599). Mean hospital length of stay was longer
in patients undergoing transplant after LVRS (29.06 days,
SD 32.82 days) compared with transplant only patients
(17.57 days, SD 16.97 days; P ¼ .005).
LVRS Outcomes
We further compared the surgical outcomes for patients
undergoing LVRS alone with those undergoing LVRS and
subsequent transplant (Table 3). Nearly all patients undergo-
ing LVRS had bilateral procedures. In pre-LVRS PFTs,
forced expiratory volume in 1 second (FEV1) percentage
predicted was significantly lower in the group undergoing
subsequent transplant compared with patients undergoing
LVRS alone (22.39%, SD 6.06% vs 27.02%, SD 7.80%,
P ¼ .003). Residual volume (RV) percentage predicted
was also higher in the group undergoing subsequent trans-
plant (262.4%, SD 54.8% vs 229.9%, SD 57.7%,
P ¼ .009) compared with LVRS alone. All other PFTs
showed no difference between groups. The data were also
examined by date of LVRSusing 2003 as a cut-off coincident
with the publication of the results of the NETT. Of patients
undergoing LVRS during the pre-NETT era (1995-2002),
16% had subsequent lung transplant compared with 4% of
patients undergoing LVRS post-NETT (2003-2010)diovascular Surgery c Volume 147, Number 5 1679
TABLE 1. Demographics
Demographics, all Transplant
LVRS þ
transplant LVRS
P
value
Total number 138 36 298
Mean age at transplant,
y (SD)
58 (6) 59 (6) .413
Mean age at LVRS, y (SD) 55 (7) 63 (8) <.001
Sex .143
Male,% (n) 44 (60) 53 (19) 54 (159)
Female,% (n) 57 (78) 47 (17) 46 (138)
Race .001
White,% 93 94 82
Nonwhite,% 5 3 3
Unknown,% 2 3 15
ATD,% (n) 10 (13) 11 (9) 17 (4) .607
Diabetes,% (n) 8 (10) 0 (0) .094
Hypertension,% (n) 37 (49) 34 (12) .802
Vascular disease,% (n) 2 (3) 6 (2) .296
Mean follow-up time,
mo (SD)*
59 (38) 50 (44) 19 (26)
LVRS, Lung volume reduction surgery; SD, standard deviation; ATD, a-1 antitrypsin
deficiency. *Follow-up time corresponds to follow-up after transplant for those
patients undergoing transplant alone or transplant and LVRS, and corresponds to
post-LVRS follow-up for patients undergoing LVRS alone.
TABLE 2. Transplant outcomes
Pretransplant variables Transplant
LVRS þ
transplant
P
value
Mean CO, L/min (SD) 5.9 (1.7) 5.7 (1.6) .555
Mean PCWP, mm Hg (SD) 12.1 (4.2) 12.8 (4.9) .483
Mean PVR, Woods units (SD) 2.2 (0.9) 4.00 (2.8) .002
Mean mPAP, mm Hg (SD) 25.2 (7.2) 26.09 (5.7) .494
Pretransplant PFTs, mean% predicted (SD)
FEV1 19.9 (5.5) 19.1 (5.3) .414
TLC 132.5 (35.5) 122.2 (19.6) .306
RV 260.1 (104.0) 238.1 (70.3) .447
DLCO 30.4 (13.5) 29.4 (8.2) .760
PCO2 50.0 (11.8) 46.3 (10.1) .092
Intraoperative variables
Cardiopulmonary bypass,% (n) 15.8 (21) 8.3 (3) .256
Mean surgery time, h (SD) 4.4 (1.2) 5.6 (1.2) .020
Mean EBL, mL (SD) 462.0 (237.6) 741.7 (1056.8) .134
Mean volume of fluids, L (SD) 2.3 (1.3) 2.8 (1.0) .258
Short-term outcomes
Mean hospital length of stay,
d (SD)
17.6 (17.0) 29.1 (32.8) .005
Mean ICU length of stay, d (SD) 7.9 (12.9) 6.2 (6.2) .545
Mean length of intubation, d (SD) 3.8 (10.7) 5.9 (19.9) .477
Lean length of chest tube, d (SD) 13.5 (12.9) 16.3 (20.4) .436
Thrombolytic events,% (n) 8.9 (12) 8.3 (3) .917
Anastomotic dehiscence,% (n) 5.1 (7) 8.3 (3) .461
Bronchopleural fistula,% (n) 2.2 (3) 2.8 (1) .845
Prolonged air leak,% (n) 16.3 (22) 13.9 (5) .725
Phrenic nerve injury,% (n) 2.2 (3) 5.6 (2) .292
Cardiothoracic Transplantation Backhus et al
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X(P ¼ .001). Mean time to listing for transplant for those un-
dergoing subsequent transplant was 48.3 months (SD 30.1
months) and mean time to transplant was 54.6 months (SD
29.0 months) months after LVRS.Tracheostomy,% (n) 2.9 (4) 5.6 (2) .447
Atrial fibrillation,% (n) 46.7 (63) 38.9 (14) .405
30-d mortality,% (n) 3.6 (5) 5.6 (2) .599
LVRS, Lung volume reduction surgery; CO, cardiac output; SD, standard deviation;
PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance;
mPAP, mean pulmonary arterial pressure;PFT, pulmonary function test; FEV1, forced
expiratory volume in 1 second; TLC, total lung capacity; RV, residual volume; DLCO,
diffusion capacity of carbon monoxide; PCO2, partial pressure of carbon dioxide; EBL,
estimated blood loss; ICU, intensive care unit.Survival Analysis
Survival analyses after LVRS demonstrated no difference
in overall survival for those undergoing LVRS alone
compared with LVRS with subsequent lung transplant
(P ¼ .492) (Figure 1).
Posttransplant survival analyses demonstrated decreased
survival for those patients undergoing transplant after
LVRS compared with those undergoing transplant alone
(P ¼ .008) (Figure 2). Posttransplant survival at 1, 5, and
10 years was 87%, 66%, and 29%, respectively, for the
transplant alone group compared with 72%, 49%, and
17%, respectively, for the combined LVRS and transplant
group. Median posttransplant survival for patients in the
transplant alone group was 96 months (95% CI, 82, 106
months). Median post-LVRS survival was 103 months
(95% CI 84, 107 months) for patients undergoing LVRS
alone. Composite survival for patients undergoing com-
bined procedures was calculated as 55 months for bridge
to transplant combined with a median posttransplant
survival of 49 months (95% CI 16, 85 months) for a total
benefit of 104 months (Figure E1).DISCUSSION
COPD is a major cause of morbidity and mortality in the
United States. Slow advancement in medical management1680 The Journal of Thoracic and Cardiovascular Surof COPD led to initial enthusiasm for surgical alternatives.9
Results from the first study of a large number of patients
undergoing surgical management of COPD via LVRS, pub-
lished in 1977, showed a 21%mortality rate. Since then, the
LVRS technique has been further refined leading to
improvements in symptoms, patient-reported quality of
life, and increased overall survival in properly selected
patients.2,4,10-16 Lung transplantation also offers
significant survival and quality of life advantages in
patients with limited life expectancy presenting with end-
stage lung disease.6-8,17,18 However, more widespread use
of lung transplantation is restricted by limited organ
availability. Consequently, wait-list mortality for lung
transplant for all diagnoses is 15.7 per 100 wait-list years.19
Providers have been biased toward offering LVRS over lung
transplantation to all qualifying patients presenting with
end-stage COPD largely because of this sobering fact
combined with the known consequences of long-termgery c May 2014
TABLE 3. LVRS outcomes
Pre-LVRS variables LVRS
LVRS þ
transplant
P
value
Pre-LVRS PFTs, mean% predicted (SD)
FEV1 27.0 (7.8) 22.4 (6.1) .003
TLC 133.3 (224.2) 131.7 (20.1) .759
RV 229.9 (57.7) 262.4 (54.8) .009
DLCO 33.2 (10.8) 31.9 (12.8) .641
PCO2 43.4 (5.5) 43.8 (7.9) .795
Date of LVRS,% (n) .001
1995-2002 84 (164) 16 (30)
2003-2010 96 (134) 4 (6)
LVRS laterality,% .643
Right 1 0
Left 2 0
Bilateral 97 100
Time from LVRS to listing, mo (SD) 48 (30)
Time from LVRS to transplant,
mo (SD)
55 (29)
LVRS, Lung volume reduction surgery; PFT, pulmonary function test; FEV1, forced
expiratory volume in 1 second; TLC, total lung capacity; RV, residual volume; DLCO,
diffusion capacity of carbon monoxide; PCO2, partial pressure of carbon dioxide; SD,
standard deviation.
FIGURE 2. Transplant survival: Kaplan-Meier survival estimates. LVRS,
Lung volume reduction surgery.
Backhus et al Cardiothoracic Transplantationimmunosuppression.20 However, mortality for patients with
COPD is less than 10 per 100 wait-list years and represents
the lowest of all diagnosis groups.19 Further support for
LVRS bias has come from reports of outcomes for patients
undergoing transplant after LVRS being comparable with
those undergoing transplant alone.20,21 One study
examined patients undergoing combined procedures from
1993 to 1997 and included 15 patients, only 7 of whom
underwent transplant ipsilateral to their LVRS
procedure.21 Another study examined the United Network
for Organ Sharing data and identified 50 patients undergo-
ing combined procedures all in the pre-NETT era from
1999 to 2002. Only 28% of patients underwent bilateralFIGURE 1. Lung volume reduction surgery survival: Kaplan-Meier
survival estimates. LVRS, Lung volume reduction surgery.
The Journal of Thoracic and Car
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Xlung transplantation and laterality of LVRS was not dis-
cussed.22 Neither study identified differences in periopera-
tive outcomes; however, small patient numbers undergoing
ipsilateral procedures and lack of patient selection after the
publication of the NETT limited both studies.
Our findings demonstrated differences in short-term and
long-term posttransplant outcomes for patients undergoing
both procedures compared with transplant alone. Although
clinically important, these differences did not reach statisti-
cal significance. Where our findings differ from previous
published reports, however, is in demonstrating reduced
posttransplant survival for patients undergoing transplant
after LVRS. The reduced posttransplant survival in patients
undergoing combined procedures might be partially ex-
plained by the longer surgical time usually because of
extensive adhesions and longer dissection requirements.
Similarly, longer hospital length of stay may also be a crude
measure pointing to the higher acuity of these patients and
may contribute to their reduced early survival. However, pa-
tients undergoing transplant after LVRS also presented with
PFTs at the time of LVRS that were much closer to the PFTs
of patients undergoing transplant alone. Although the mean
values for FEV1, RV, diffusion capacity of carbon monox-
ide, and total lung capacity were all outside the high-risk
category by the NETT criteria for LVRS, they still repre-
sented more severe disease at the time of initial presenta-
tion. The equivalent post-LVRS survival for patients
undergoing LVRS alone versus transplant after LVRS may
be a reflection of the added value of transplant in rescuing
these more severely affected patients from otherwise
reduced survival in the absence of lung transplantation. A
study examining outcomes of 99 patients who were candi-
dates for both procedures described 15 patients who went
on to have lung transplantation at a mean time of 45.6
months. The investigators found that these patients were
younger, more impaired (reduced FEV1, increased RV,
and disease more predominantly in the lower lobe) anddiovascular Surgery c Volume 147, Number 5 1681
Cardiothoracic Transplantation Backhus et al
T
Xhad less benefit from their LVRS procedure than the others
who did not receive transplantation.23 Another study re-
ported experience from 27 patients undergoing transplant
after previous LVRS. The investigators reported a mean
bridge time of 29.7 months and examined posttransplant
survival for patients undergoing both procedures by subdi-
viding them into those who did well after LVRS compared
with those who did not as shown by improvement in FEV1
and body mass index. The investigators did not compare
preoperative pulmonary function or posttransplant survival
with patients undergoing transplant alone as we did in this
study. They do report nonupper lobe predominant emphy-
sema distribution associated with poor outcomes after
LVRS and subsequent poor outcomes after lung transplan-
tation.24 Others have also conceded that patients who
benefit most from LVRS are those with less severe disease
at presentation.20 These findings underscore the importance
of patient selection at the time of initial presentation for
LVRS in predicting posttransplant outcomes.
Our study is limited by incomplete data for the LVRS
group and for long-term follow-up. Other factors not
captured in this dataset include acute rejection episodes
and bronchiolitis obliterans, which might also help explain
the observed difference in survival. We did not have infor-
mation regarding the distribution of emphysema, which is
critical for determining the estimated benefit of LVRS.
Our study also included patients evaluated for LVRS both
before (1995-2002) and after (2003-2010) publication of
the results of NETT.We did examine our results using these
time cut-offs and found that the difference in survival per-
sisted (data not shown). Also during the study period, the
lung allocation score (LAS) was introduced, however under
the LAS, patients with emphysema have been deprioritized
for transplant thus one would expect to see a potential
decrease in the number of transplants being performed for
COPD and a potential increase in the number of LVRS pro-
cedures, which was not observed. Nonetheless, improve-
ments in patient selection for candidacy for LVRS may
indeed have played a role in our reported outcomes.
On a larger scale, the benefits of the use of combined pro-
ceduresmust be evaluated in the context of overall benefits as
well as health care resource allocation.Wedefined composite
survival as the bridge time between LVRS and subsequent
lung transplantation combined with posttransplant survival.
Patients undergoing both procedures had composite survival
similar to survival after either procedure alone, but at the
expense of reduced posttransplant survival and use of 2 sur-
gical procedures. This difference is not trivial. Although it
can be argued that the end result of equivalent survival jus-
tifies the means, we would counter that this justification
deserves closer scrutiny. Clearly there are substantial benefits
to delaying entry into the world of posttransplant care, with
concomitant risks associated with immunosuppression.
However, if the more severely affected patient with1682 The Journal of Thoracic and Cardiovascular Surend-stage COPD eventually requires a lung transplant even
after LVRS in order to receive optimal benefit, that patient
might be better served with lung transplant as the single sur-
gical intervention. Patients undergoing lung transplantation
do experience a higher level of functional status, greater im-
provements in airflow obstruction, dyspnea, and exercise
tolerance compared with patients undergoing LVRS and
these effects are more durable than with LVRS.25 Overall,
however, the cost of lung transplant is roughly twice that of
LVRS at 2 years. Thus, if we are to consider the benefits of
both surgical procedures as additive, so too are the costs.
Our findings are particularly relevant given the increasing
costs of health care with renewed emphasis on cost contain-
ment and advocacy. Some encourage pushing the limits of
LVRS by offering it to more marginal patients including
those defined as high risk by the NETT criteria.23 The
choice of surgical modality is straightforward in some pa-
tients. Patients who do not meet the high-risk criteria for
NETT and otherwise do not straddle the line between
LVRS and pretransplant clinical parameters should be
offered LVRS as their definitive surgical therapy. In many
cases, improvement in symptoms and quality of life may
be sufficient to defer or eliminate the need for lung trans-
plant altogether. Likewise, patients with depressed lung
function too severe for consideration of LVRS should be
referred directly to transplantation. For patients who have
marginal function, but otherwise meet the criteria for
LVRS, particularly younger patients, lung transplant might
be offered with similar outcomes and maximal benefit
conferred per organ used. Few patients potentially fall
into this category as they likely represent a small subgroup
of patients who should be best served by a single surgical
intervention for management of their COPD.References
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FIGURE E1. Composite survival benefit. *Lung volume reduction sur-
gery survival for combined surgical treatment listed as time from lung vol-
ume reduction surgery to time to transplant. LVRS, Lung volume reduction
surgery.
Cardiothoracic Transplantation Backhus et al
1683.e1 The Journal of Thoracic and Cardiovascular Surgery c May 2014
T
X
